These differences persisted over time.An increase in bone or joint pain was more pronounced, particularly in the short term, in patients who received exemestane plus ovarian function suppression than in patients who received tamoxifen plus ovarian function suppression.Changes in global QOL indicators from baseline were small and similar between treatments over the 5 years.[59][Level of evidence A3] The use of exemestane resulted in a significant difference in DFS.
The 8-year DFS rate was 86.8% in the exemestane-ovarian suppression group vs.
82.8% in the tamoxifen-ovarian suppression group (HR, 0.77; 95% CI, 0.67â€“0.90;P< .001).[57][Level of evidence B1] The 8-year rate of freedom from distant recurrence was also higher in the exemestane-ovarian suppression group (91.8% vs.